Daejeon, South Korea

Joo Youn Lee

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Daejeon, KR (2020 - 2021)
  • Gimpo-si, KR (2024)

Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Joo Youn Lee

Introduction

Joo Youn Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals and biotechnology, holding a total of 4 patents. His work focuses on developing innovative solutions for various health-related issues.

Latest Patents

Among his latest patents is an inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like. This invention serves as an anticancer agent and is effective in treating hyperlipidemia. The NSDHL inhibitor can not only act as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents but also provides advantages in the treatment of hyperlipidemia. Another notable patent involves a peptide for treating rheumatoid arthritis, which includes a specific amino acid sequence and is designed for use in pharmaceutical compositions or health functional food compositions aimed at improving rheumatoid arthritis.

Career Highlights

Joo Youn Lee has worked with esteemed institutions such as the Korea Research Institute of Chemical Technology and Seoul National University. His experience in these organizations has contributed to his expertise in chemical technology and pharmaceutical research.

Collaborations

Throughout his career, Joo Youn Lee has collaborated with notable colleagues, including Jong Yeon Hwang and Jae Du Ha. These partnerships have facilitated the advancement of his research and innovations.

Conclusion

Joo Youn Lee's contributions to the field of pharmaceuticals and biotechnology are noteworthy. His innovative patents and collaborations reflect his commitment to addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…